Trial Profile

An Open-label, Non-randomized Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of LNP023 in Two Patient Populations With C3 Glomerulopathy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Iptacopan (Primary)
Indications Membranoproliferative glomerulonephritis; Proteinuria
Focus Therapeutic Use
Sponsors Novartis Pharmaceuticals

Most Recent Events

25 May 2024 According to a Novartis media release, long-term 33-month efficacy and safety data to be presenting at European Renal Association (ERA) Congress.
04 Nov 2021 According to a Novartis media release, data from the study were presented at the American Society of Nephrology (ASN) 2021 Annual Meeting.
04 Nov 2021 Results published in the Novartis Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com